keyword
MENU ▼
Read by QxMD icon Read
search

Branch retinal vein

keyword
https://www.readbyqxmd.com/read/28441077/comparison-of-conbercept-with-ranibizumab-for-the-treatment-of-macular-edema-secondary-to-branch-retinal-vein-occlusion
#1
Fengjiao Li, Ming Sun, Jianlian Guo, Aihua Ma, Bojun Zhao
PURPOSE: To confirm the therapeutic efficacy of conbercept for the treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO). METHODS: In this prospective, randomized, and comparative study, patients were randomized and divided into conbercept (n = 18) and ranibizumab (n = 17) groups. After an initial intravitreal injection of either conbercept or ranibizumab, a pro re nata (PRN) strategy was adopted based on loss of visual acuity (VA) or increase in central macular thickness (CMT)...
April 25, 2017: Current Eye Research
https://www.readbyqxmd.com/read/28440254/combined-branch-retinal-vein-and-branch-retinal-artery-occlusion-clinical-features-systemic-associations-and-outcomes
#2
Sabyasachi Sengupta, Utsab Pan
PURPOSE: Retinal vascular occlusions affecting both the arterial and venous systems are rare events. Combined branch retinal artery (BRAO) and vein (BRVO) occlusion are exceedingly rare and not well characterized. METHODS: Six patients with combined BRAO and BRVO underwent a comprehensive eye examination, fundus fluorescein angiography, optical coherence tomography, and cardiovascular evaluation. RESULTS: Mean age at presentation was 54 ± 7...
March 2017: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/28435211/erratum-prolongation-of-injection-interval-after-switching-therapy-from-ranibizumab-to-aflibercept-in-japanese-patients-with-macular-edema-secondary-to-branch-retinal-vein-occlusion-corrigendum
#3
(no author information available yet)
[This corrects the article on p. 403 in vol. 11, PMID: 28260852.].
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28432581/comparison-of-immediate-versus-deferred-intravitreal-bevacizumab-in-macular-oedema-due-to-branch-retinal-vein-occlusion-a-pilot-study
#4
M A Khan, Varakutti Mallika, Dattakiran Joshi
PURPOSE: To compare visual and anatomical recovery of immediate versus deferred intravitreal Bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion (BRVO). METHODS: In a pilot study, 40 treatment naïve patients of branch retinal vein occlusion with macular oedema and vision 6/12 or less presenting within one month of onset were randomised into 2 groups (20 each) to receive either immediate intravitreal Bevacizumab or deferred (after 3 months of observation)...
April 21, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28390895/observation-and-characterization-of-microvascular-vasomotion-using-erythrocyte-mediated-icg-angiography-em-icg-a
#5
Robert W Flower, Ronn Kling
A clinical method for characterizing the state of micro-vasculature vasomotion is demonstrated, based on observing in capillaries the dynamics of autologously re-injected erythrocytes containing ICG dye. Since a manifestation of vasomotion is transient erythrocyte pausing, vasomotion state within a field of capillaries is characterized by an histogram plot of the number of paused erythrocytes as a function of pause duration during a fixed period of observation, then the ratio of long-pausing to short-pausing erythrocytes was calculated...
April 5, 2017: Microvascular Research
https://www.readbyqxmd.com/read/28388705/retinal-microvasculature-and-visual-acuity-in-eyes-with-branch-retinal-vein-occlusion-imaging-analysis-by-optical-coherence-tomography-angiography
#6
Taku Wakabayashi, Tatsuhiko Sato, Chikako Hara-Ueno, Yoko Fukushima, Kaori Sayanagi, Nobuhiko Shiraki, Miki Sawa, Yasushi Ikuno, Hirokazu Sakaguchi, Kohji Nishida
Purpose: To investigate microvascular changes in the superficial capillary plexus (SCP) and deep capillary plexus (DCP) in eyes with resolved branch retinal vein occlusion (BRVO) and their association with best-corrected visual acuity (BCVA). Methods: Eighty-five eyes (82 consecutive patients) with BRVO after resolution of the macular edema were retrospectively evaluated. All patients underwent optical coherence tomography angiography (OCTA) for assessment of microvascular changes, including capillary telangiectasia, microaneurysm, and disruption of the foveal avascular zone (FAZ)...
April 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28386476/new-developments-in-the-classification-pathogenesis-risk-factors-natural-history-and-treatment-of-branch-retinal-vein-occlusion
#7
REVIEW
Jia Li, Yannis M Paulus, Yuanlu Shuai, Wangyi Fang, Qinghuai Liu, Songtao Yuan
For years, branch retinal vein occlusion is still a controversial disease in many aspects. An increasing amount of data is available regarding classification, pathogenesis, risk factors, natural history, and therapy of branch retinal vein occlusion. Some of the conclusions may even change our impression of branch retinal vein occlusion. It will be beneficial for our doctors to get a deeper understanding of this disease and improve the treatment skills. The aims of this review is to collect the information above and report new ideas especially from the past a few years...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28384724/gap-in-capillary-perfusion-on-optical-coherence-tomography-angiography-associated-with-persistent-macular-edema-in-branch-retinal-vein-occlusion
#8
Kotaro Tsuboi, Yuichiro Ishida, Motohiro Kamei
Purpose: To evaluate correlations between persistent macular edema associated with branch retinal vein occlusion (BRVO) and the macular perfusion status in the superficial capillary plexus (SCP) and deep capillary plexus (DCP) using optical coherence tomography angiography (OCTA). Methods: Retrospective, case-control study. Twenty patients with BRVO followed for 12 months or more were enrolled. Persistent macular edema was defined as central retinal thickness exceeding 300 μm that persisted or recurred less than 3 months after the final treatment...
April 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28379652/quantitative-reduction-in-central-foveal-thickness-after-first-anti-vegf-injection-as-a-predictor-of-final-outcome-in-brvo-patients
#9
Rupak Roy, Kumar Saurabh, Avirupa Ghose, Dhileesh P Chandrasekharan, Preeti Sharma, Swakshyar Saumya Pal, Sudipta Das
PURPOSE: To analyze the predictive ability of quantitative reduction in central foveal thickness (CFT) after the first antivascular endothelial growth factor (anti-VEGF) injection to assess final outcome in branch retinal vein occlusion (BRVO) patients. DESIGN: A retrospective interventional consecutive case series. METHODS: We retrospectively reviewed 60 treatment-naive BRVO patients. All the patients were treated with bevacizumab injection pro re nata...
March 29, 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/28367038/dexamethasone-intravitreal-implant-rescue-treatment-for-bevacizumab-refractory-macular-edema-secondary-to-branch-retinal-vein-occlusion
#10
Kyou Ho Lee, Eui Chun Kang, Hyoung Jun Koh
PURPOSE: To evaluate the prognostic factors and outcomes of dexamethasone intravitreal implant (DEX implant) for intravitreal bevacizumab refractory macular edema secondary to branch retinal vein occlusion (BRVO). METHODS: This was a retrospective, interventional case series. Medical records were reviewed, and a total of 38 eyes that were treated with DEX implant for macular edema secondary to BRVO that did not respond to at least two consecutive intravitreal bevacizumab injections (IBIs) were included...
April 2017: Korean Journal of Ophthalmology: KJO
https://www.readbyqxmd.com/read/28367036/natural-short-term-course-of-recurrent-macular-edema-following-intravitreal-bevacizumab-therapy-in-branch-retinal-vein-occlusion
#11
Su Jin Yoo, Jae Hui Kim, Tae Gon Lee, Jong Woo Kim, Sung Won Cho, Jung Il Han
PURPOSE: To evaluate the 3-month natural course of recurrent macular edema secondary to branch retinal vein occlusion (BRVO) treated with intravitreal bevacizumab. METHODS: This retrospective, observational study included 36 eyes with macular edema secondary to BRVO. All patients were initially treated with intravitreal bevacizumab for macular edema. Recurrence of macular edema was either not treated (untreated group) or treated with a single intravitreal bevacizumab injection (treated group)...
April 2017: Korean Journal of Ophthalmology: KJO
https://www.readbyqxmd.com/read/28365905/aflibercept-a-review-in-macular-oedema-secondary-to-branch-retinal-vein-occlusion
#12
Sheridan M Hoy
Aflibercept (Eylea(®)) is a fully human, recombinant fusion protein available in various countries worldwide, including those of the EU, as well as the USA, for intravitreal use in the treatment of macular oedema secondary to branch retinal vein occlusion (BRVO) in adults. Aflibercept acts as a soluble decoy receptor, binding with high affinity to vascular endothelial growth factor (VEGF)-A and placental growth factor (PIGF), preventing these angiogenic factors from binding to and activating their cognate receptors...
April 1, 2017: Drugs & Aging
https://www.readbyqxmd.com/read/28336566/branch-retinal-vein-occlusion-secondary-to-sildenafil
#13
Hussein Almuhtaseb, Osama Kanavati, Andrew Lotery
No abstract text is available yet for this article.
March 23, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28334720/intravitreal-dexamethasone-implant-versus-intravitreal-ranibizumab-for-the-treatment-of-macular-edema-secondary-to-retinal-vein-occlusion-in-a-chinese-population
#14
Xiaoya Gu, Xiaobing Yu, Shuang Song, Hong Dai
BACKGROUND: The aim of this work was to compare the efficacy of intravitreal dexamethasone implant (Ozurdex) and intravitreal ranibizumab (Lucentis) in the treatment of macular edema (ME) caused by retinal vein occlusion (RVO). METHODS: Thirty-two ME cases treated with Ozurdex and 32 ME cases treated with ranibizumab were enrolled, with 26 central (C)RVO and 6 branch (B)RVO subjects in each group. We compared the results of best-corrected visual acuity (BCVA), central retinal thickness, number of injections, and intraocular pressure (IOP) at 1, 2, 3, and 6 months after injection...
March 24, 2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28315518/real-world-outcomes-of-anti-vegf-treatment-for-retinal-vein-occlusion-in-portugal
#15
Sara Vaz-Pereira, Inês P Marques, João Matias, Filipe Mira, Lígia Ribeiro, Rita Flores
PURPOSE: Retinal vein occlusion (RVO) is an important cause of visual disability in the modern world. We aim to evaluate the real-world outcomes of patients with RVO treated with anti-vascular endothelial growth factor (VEGF) in Portugal. METHODS: We performed a retrospective, observational, multicenter study including 8 centers across Portugal and 200 patients treated with either ranibizumab or bevacizumab. Data were collected at 3 time points: time of diagnosis (0 time point) and 6 and 12 months after initiating treatment...
February 28, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28315513/increased-fibrinogen-to-albumin-ratio-in-ischemic-retinal-vein-occlusions
#16
Hande Guclu, Sadık A Ozal, Vuslat Pelitli Gurlu, Gülben Sayılan Özgün, Eray Özgün
PURPOSE: To demonstrate the relationship between ischemia and plasma fibrinogen and serum albumin levels in cases of retinal vein occlusion (RVO). METHODS: This study included 44 patients with central RVO (CRVO), 68 patients with branch RVO (BRVO), and 54 age- and sex-matched controls, for a total of 166 subjects. All of the subjects underwent full ophthalmologic examinations and complete physical examinations, including a detailed medical history and blood count, and biochemical parameters...
March 3, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28295554/branch-retinal-vein-occlusion-following-cataract-surgery
#17
Silvio Polizzi, Francesco Barca, Tomaso Caporossi, Gianni Virgili, Stanislao Rizzo
No abstract text is available yet for this article.
March 12, 2017: Clinical & Experimental Optometry: Journal of the Australian Optometrical Association
https://www.readbyqxmd.com/read/28288603/a-cute-angle-closure-attack-after-an-intravitreal-bevacizumab-injection-for-branch-retinal-vein-occlusion-a-case-report
#18
Seongyong Jeong, Min Sagong, Woohyok Chang
BACKGROUND: Intravitreal injection is widely used to treat retinal vein occlusion, and acute angle closure (AAC) is an exceptional complication of intravitreal injection. The authors report a case of AAC that occurred immediately after administering intravitreal bevacizumab to treat branch retinal vein occlusion (BRVO). CASE PRESENTATION: A 65-year-old woman was referred to the retina clinic of a tertiary referral center for the treatment of macular edema secondary to BRVO...
March 14, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28266152/macular-cystic-changes-as-predictive-factor-for-the-recurrence-of-macular-oedema-in-branch-retinal-vein-occlusion
#19
Eric Tilgner, Maiara Dalcegio Favretto, Maria Tuisl, Peter Wiedemann, Matus Rehak
AIM: To evaluate the role of small cystic macular changes as a prognostic factor for the recurrence of macular oedema (ME) in patients with branch retinal vein occlusion (BRVO) treated with anti-VEGF drugs. METHODS: We performed retrospective chart analysis of 116 patients treated with intravitreal injection of ranibizumab (IVR) or bevacizumab (IVB) for ME secondary to BRVO. At the baseline and monthly follow-up visits over a period of 12 months, a comprehensive ophthalmologic examination including best-corrected visual acuity (BCVA) and volume scan of macula using Spectral domain optical coherence tomography (SD-OCT) were performed...
March 7, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28260852/prolongation-of-injection-interval-after-switching-therapy-from-ranibizumab-to-aflibercept-in-japanese-patients-with-macular-edema-secondary-to-branch-retinal-vein-occlusion
#20
Mizuki Tagami, Ryuto Sai, Masahide Fukuda, Atsushi Azumi
PURPOSE: This study was conducted to investigate the outcome of switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO) in daily practice. MATERIALS AND METHODS: This retrospective study enrolled 15 eyes in 15 Japanese patients with ME secondary to BRVO who had been receiving a pro re nata regimen of ranibizumab and had provided written informed consent to switch to aflibercept therapy...
2017: Clinical Ophthalmology
keyword
keyword
53074
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"